NRx Pharmaceuticals (NRXP) Competitors

$3.28 +0.07 (+2.18%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$3.22 -0.06 (-1.83%)

As of 05/15/2026 07:58 PM Eastern

NRXP vs. ALT, RCKT, CLLS, PBYI, and SNDL

Should you buy NRx Pharmaceuticals stock or one of its competitors? MarketBeat compares NRx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NRx Pharmaceuticals include Altimmune (ALT), Rocket Pharmaceuticals (RCKT), Cellectis (CLLS), Puma Biotechnology (PBYI), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry.

How does NRx Pharmaceuticals compare to Altimmune?

NRx Pharmaceuticals (NASDAQ:NRXP) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

NRx Pharmaceuticals has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. NRx Pharmaceuticals' return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-207.44%
Altimmune	-214,860.98%	-42.57%	-35.57%

NRx Pharmaceuticals currently has a consensus price target of $38.25, suggesting a potential upside of 1,066.16%. Altimmune has a consensus price target of $17.50, suggesting a potential upside of 514.04%. Given NRx Pharmaceuticals' higher probable upside, research analysts plainly believe NRx Pharmaceuticals is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Altimmune had 9 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 13 mentions for Altimmune and 4 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 0.78 beat Altimmune's score of 0.34 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NRx Pharmaceuticals has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	88.19	-$28.62M	-$1.39	N/A
Altimmune	$40K	9,269.63	-$88.09M	-$0.93	N/A

NRx Pharmaceuticals has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

Summary

NRx Pharmaceuticals beats Altimmune on 9 of the 15 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Rocket Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

NRx Pharmaceuticals has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

NRx Pharmaceuticals' return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-207.44%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

In the previous week, Rocket Pharmaceuticals had 14 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 18 mentions for Rocket Pharmaceuticals and 4 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 0.78 beat Rocket Pharmaceuticals' score of 0.16 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NRx Pharmaceuticals has higher revenue and earnings than Rocket Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	88.19	-$28.62M	-$1.39	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

NRx Pharmaceuticals currently has a consensus price target of $38.25, suggesting a potential upside of 1,066.16%. Rocket Pharmaceuticals has a consensus price target of $11.54, suggesting a potential upside of 255.03%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe NRx Pharmaceuticals is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rocket Pharmaceuticals	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

NRx Pharmaceuticals beats Rocket Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Cellectis?

NRx Pharmaceuticals (NASDAQ:NRXP) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

NRx Pharmaceuticals has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.94, indicating that its share price is 194% more volatile than the broader market.

NRx Pharmaceuticals has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. NRx Pharmaceuticals' return on equity of 0.00% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-207.44%
Cellectis	-89.51%	-80.66%	-20.51%

In the previous week, Cellectis had 2 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 6 mentions for Cellectis and 4 mentions for NRx Pharmaceuticals. Cellectis' average media sentiment score of 1.04 beat NRx Pharmaceuticals' score of 0.78 indicating that Cellectis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectis	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NRx Pharmaceuticals has higher earnings, but lower revenue than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	88.19	-$28.62M	-$1.39	N/A
Cellectis	$79.59M	4.94	-$67.59M	-$0.67	N/A

NRx Pharmaceuticals currently has a consensus price target of $38.25, suggesting a potential upside of 1,066.16%. Cellectis has a consensus price target of $6.75, suggesting a potential upside of 72.19%. Given NRx Pharmaceuticals' higher possible upside, equities analysts clearly believe NRx Pharmaceuticals is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Cellectis beats NRx Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

NRx Pharmaceuticals has a consensus target price of $38.25, suggesting a potential upside of 1,066.16%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Puma Biotechnology has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

Puma Biotechnology has a net margin of 10.69% compared to NRx Pharmaceuticals' net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat NRx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
NRx Pharmaceuticals	N/A	N/A	-207.44%

In the previous week, Puma Biotechnology and Puma Biotechnology both had 4 articles in the media. NRx Pharmaceuticals' average media sentiment score of 0.78 beat Puma Biotechnology's score of 0.47 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Puma Biotechnology has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.54	$31.11M	$0.48	14.42
NRx Pharmaceuticals	$1.23M	88.19	-$28.62M	-$1.39	N/A

Summary

Puma Biotechnology beats NRx Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to SNDL?

SNDL (NASDAQ:SNDL) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

SNDL currently has a consensus target price of $5.00, suggesting a potential upside of 249.65%. NRx Pharmaceuticals has a consensus target price of $38.25, suggesting a potential upside of 1,066.16%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than SNDL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SNDL	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SNDL has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

NRx Pharmaceuticals has a net margin of 0.00% compared to SNDL's net margin of -1.19%. NRx Pharmaceuticals' return on equity of 0.00% beat SNDL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SNDL	-1.19%	-1.02%	-0.85%
NRx Pharmaceuticals	N/A	N/A	-207.44%

In the previous week, NRx Pharmaceuticals had 3 more articles in the media than SNDL. MarketBeat recorded 4 mentions for NRx Pharmaceuticals and 1 mentions for SNDL. SNDL's average media sentiment score of 1.89 beat NRx Pharmaceuticals' score of 0.78 indicating that SNDL is being referred to more favorably in the media.

Company	Overall Sentiment
SNDL	Very Positive
NRx Pharmaceuticals	Positive

SNDL has higher revenue and earnings than NRx Pharmaceuticals. SNDL is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SNDL	$677.32M	0.54	-$11.29M	-$0.03	N/A
NRx Pharmaceuticals	$1.23M	88.19	-$28.62M	-$1.39	N/A

Summary

NRx Pharmaceuticals beats SNDL on 10 of the 15 factors compared between the two stocks.

Get NRx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRXP vs. The Competition

Export

Metric	NRx Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$108.46M	$3.00B	$6.37B	$12.30B
Dividend Yield	N/A	1.95%	2.80%	5.26%
P/E Ratio	-3.01	17.57	20.42	25.27
Price / Sales	88.19	281.21	533.26	62.09
Price / Cash	N/A	57.31	42.43	54.86
Price / Book	-6.07	4.33	9.87	6.90
Net Income	-$28.62M	$72.19M	$3.57B	$334.66M
7 Day Performance	6.49%	-3.06%	0.23%	0.12%
1 Month Performance	28.63%	-5.08%	-2.54%	-0.18%
1 Year Performance	33.88%	36.79%	33.54%	30.62%

NRx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRXP NRx Pharmaceuticals	2.9174 of 5 stars	$3.28 +2.2%	$38.25 +1,066.2%	+33.9%	$108.46M	$1.23M	N/A	2	News Coverage Earnings Report Upcoming Earnings
ALT Altimmune	3.5663 of 5 stars	$3.09 flat	$18.00 +482.5%	-48.9%	$402.02M	$40K	N/A	50	News Coverage Earnings Report Analyst Forecast
RCKT Rocket Pharmaceuticals	2.332 of 5 stars	$3.59 -1.1%	$11.54 +221.4%	-50.0%	$396.12M	N/A	N/A	240	Analyst Downgrade Analyst Revision
CLLS Cellectis	2.8727 of 5 stars	$3.98 +3.4%	$6.75 +69.6%	+148.1%	$386.31M	$79.59M	N/A	290	Positive News Earnings Report
PBYI Puma Biotechnology	1.4403 of 5 stars	$7.14 -4.7%	N/A	+104.1%	$381.24M	$228.40M	14.88	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRXP) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NRx Pharmaceuticals (NRXP) Competitors

NRXP vs. ALT, RCKT, CLLS, PBYI, and SNDL

How does NRx Pharmaceuticals compare to Altimmune?

Summary

How does NRx Pharmaceuticals compare to Rocket Pharmaceuticals?

Summary

How does NRx Pharmaceuticals compare to Cellectis?

Summary

How does NRx Pharmaceuticals compare to Puma Biotechnology?

Summary

How does NRx Pharmaceuticals compare to SNDL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP vs. The Competition

NRx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NRx Pharmaceuticals (NRXP) Competitors

NRXP vs. ALT, RCKT, CLLS, PBYI, and SNDL

How does NRx Pharmaceuticals compare to Altimmune?

Is NRXP or ALT more profitable?

Do analysts prefer NRXP or ALT?

Do institutionals and insiders hold more shares of NRXP or ALT?

Does the media favor NRXP or ALT?

Which has preferable earnings and valuation, NRXP or ALT?

Which has more risk and volatility, NRXP or ALT?

Summary

How does NRx Pharmaceuticals compare to Rocket Pharmaceuticals?

Which has more volatility & risk, NRXP or RCKT?

Is NRXP or RCKT more profitable?

Does the media favor NRXP or RCKT?

Which has better valuation & earnings, NRXP or RCKT?

Do analysts prefer NRXP or RCKT?

Do insiders & institutionals hold more shares of NRXP or RCKT?

Summary

How does NRx Pharmaceuticals compare to Cellectis?

Which has more volatility & risk, NRXP or CLLS?

Is NRXP or CLLS more profitable?

Does the media favor NRXP or CLLS?

Which has better valuation & earnings, NRXP or CLLS?

Do analysts prefer NRXP or CLLS?

Do insiders & institutionals hold more shares of NRXP or CLLS?

Summary

How does NRx Pharmaceuticals compare to Puma Biotechnology?

Do analysts prefer PBYI or NRXP?

Do institutionals & insiders hold more shares of PBYI or NRXP?

Which has more risk & volatility, PBYI or NRXP?

Is PBYI or NRXP more profitable?

Does the media refer more to PBYI or NRXP?

Which has preferable valuation and earnings, PBYI or NRXP?

Summary

How does NRx Pharmaceuticals compare to SNDL?

Do analysts prefer SNDL or NRXP?

Do institutionals & insiders hold more shares of SNDL or NRXP?

Which has more risk & volatility, SNDL or NRXP?

Is SNDL or NRXP more profitable?

Does the media refer more to SNDL or NRXP?

Which has preferable valuation and earnings, SNDL or NRXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP vs. The Competition

NRx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools